Pulsante(R) Microstimulator System Offers Cluster Headache Patients New Hope — Minimally-Invasive Treatment Now Available in Nine European Countries
Pulsante(R) Microstimulator System Offers Cluster Headache Patients New Hope — Minimally-Invasive Treatment Now Available in Nine European Countries
BEAVERTON, OR — (Marketwired) — 11/23/15 — Cascade Microtech, Inc. (NASDAQ: CSCD), a leading supplier of solutions that enable precision measurements of integrated circuits at the wafer level, today announced it will participate in the 4th Annual Midtown CAP Investor Summit 2015, being held December 10, 2015 at the Le Parker Méridien Hotel, New York, NY. Cascade Microtech–s president and CEO, Michael Burger, and CFO Jeff Killian will join executive management from other participating
MILWAUKEE, WI — (Marketwired) — 11/16/15 — EnSync, Inc. (NYSE MKT: ESNC), dba , a leading developer of innovative energy management systems for the utility, commercial, industrial and multi-tenant building markets, today announced their first quarter 2016 results."All the required pieces are coming together here at EnSync and we have made great progress building the foundation for our future success," said Brad Hansen CEO and President of EnSync. "Early this year we announced
MOUNTAIN VIEW, CA — (Marketwired) — 11/16/15 — Hansen Medical, Inc. (NASDAQ: HNSN), the global leader in intravascular robotics, today announced it will exhibit its Magellan Robotic System at the 42nd Annual VEITHsymposium®, November 17 – 21 at the New York Hilton-Midtown in New York City. The Company will be conducting product demonstrations of the Magellan Robotic System and the related family of Magellan Robotic Catheters, including the Magellan 6Fr, 9Fr and 10Fr catheters. Hansen Med
deadman mode Safe Combat Training Tips and Some kiss in Deadman
UP TO 90% OFF on RSorder Thanksgiving Special Promos
$6000 cash free fiveaways on RSorder Pandora–s box for thanksgiving
MOUNTAIN VIEW, CA — (Marketwired) — 11/05/15 — Hansen Medical, Inc. (NASDAQ: HNSN), the global leader in intravascular robotics, today reported recent business highlights and financial results for the third quarter ended September 30, 2015.The Company today announces a broad cost reduction program, which when fully implemented, is expected to further reduce the break-even point of the company to approximately $40 million in annual revenue, improve cash flow and allow for further investment i
New EVA100 Production Model Offers Versatile, Easy-to-Use Test Solution for Applications From Design Evaluation to Volume Production
First Clinical Case Performed at Hopital Europeen Georges Pompidou (HEGP-APHP)